On December 19, 2023 NanOlogy LLC, a clinical-stage oncology company, reported data presented as posters during recent oncology conferences (Press release, NanOlogy, DEC 19, 2023, View Source;utm_medium=rss&utm_campaign=nanology-clinical-and-preclinical-immune-data-presented-at-naclc-and-sitc [SID1234638683]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A poster entitled Phase 2a Intratumoral Large Surface Area Microparticle Paclitaxel in Stage 3/4 Lung Cancer was presented during IASLC’s North American Conference on Lung Cancer in Chicago on December 2, 2023. The poster was authored by clinical investigators Hiren Mehta, Abhishek Biswas, Sarah Wang, Jason Akulian, Christine Argento, et.al. It was one of only about 10% of posters selected for discussion during the poster discussion session. Summarizing presented data:
The early phase lung cancer trial demonstrated safety and tolerability of intratumoral (IT) LSAM-PTX in combination with various concurrent therapies including systemic immunotherapy.
Disease Control Rate for evaluable subjects at 3- and 6-months was 80% (8/10) and 86% (6/7), respectively.
Flow cytometry and safety data suggest IT LSAM-PTX may cause immunomodulation, including increases in immune effectors cells and decreases in Tregs and immune suppressor cells, and complement systemic therapy without significantly increasing adverse events.
A poster entitled Local administration of large surface area microparticle docetaxel is associated with antitumor immunomodulation across multiple tumor types was presented during the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting on November 4, 2023. The poster was authored by Holly Maulhardt, Alyson Marin, et.al. Summarizing presented data:
Immunophenotyping in 3 diverse tumor settings found commonalities in antitumor immunomodulation following local LSAM-DTX including changes in T cells and MDSCs.
NMIBC clinical subjects demonstrated infiltrations of CD4+T, CD8+ T, and NK cells.
Mice administered IT LSAM-DTX into renal tumor xenografts had increased circulating T cells and reduced M2-macrophage levels in the blood and spleen when compared to IV docetaxel.
IT LSAM-DTX in a metastatic breast cancer model increased T cells in the TME and reduced thoracic metastasis when combined with systemic immunotherapy.
Preclinical/clinical antitumor immunomodulation suggests that IT LSAM-DTX may be amenable to combination with immunotherapy.